» Articles » PMID: 11062803

Invasive Pneumococcal Disease in the Northern Territory of Australia, 1994-1998

Overview
Journal Med J Aust
Specialty General Medicine
Date 2000 Nov 4
PMID 11062803
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the epidemiology of invasive pneumococcal disease (IPD) in the Northern Territory of Australia as a basis for optimising vaccination and healthcare provision.

Design: Prospective laboratory surveillance, with information collected from hospital and clinic records.

Setting: Northern Territory (NT) and rural communities in north-west South Australia served by an NT hospital, 1994-1998 (NT population is 27% Indigenous).

Main Outcome Measures: IPD incidence and mortality, risk factors, clinical presentation and disease-causing serotypes in Indigenous and non-Indigenous people.

Results: 425 cases of IPD were detected, with 77% in Indigenous people. IPD incidence was highest in Indigenous children aged < 2 years (1534 per 100,000 in central Australia), but about 100 per 100,000 in non-Indigenous children < 2 years and all Indigenous age groups aged > or = 15 years. Mean ages of those with disease were 39 years in Indigenous people and 48 years in non-Indigenous people (P = 0.006) and, of those who died, 41 and 53 years, respectively (P = 0.04). IPD risk factors were present in 72% of Indigenous and 55% of non-Indigenous patients aged > or = 2 years. Serotype results for 363 isolates showed that the 23-valent vaccine covered 68% and 85% of isolates from Indigenous and non-Indigenous people aged > or = 2 years, respectively, while the proposed seven-, nine- and 11-valent conjugate vaccines covered 58%, 66% and 67% of isolates, respectively, from Indigenous children aged < 2 years and 72% each of those from non-Indigenous children. Case-fatality rates were 10% in both Indigenous and non-Indigenous people.

Conclusion: These data support the recent change in NT vaccination policy which extended funding for the 23-valent vaccine to all Indigenous people aged > or = 15 years and all Indigenous children in central Australia aged 2-5 years. The high rates of IPD in both Indigenous and non-Indigenous children mandate action to make conjugate vaccine available as soon as possible.

Citing Articles

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Feikin D, Kagucia E, Loo J, Link-Gelles R, Puhan M, Cherian T PLoS Med. 2013; 10(9):e1001517.

PMID: 24086113 PMC: 3782411. DOI: 10.1371/journal.pmed.1001517.


Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease.

Mackenzie G, Leach A, Carapetis J, Fisher J, Morris P BMC Infect Dis. 2010; 10:304.

PMID: 20969800 PMC: 2974682. DOI: 10.1186/1471-2334-10-304.


Effectiveness of 7-valent pneumococcal conjugate vaccine against radiologically diagnosed pneumonia in indigenous infants in Australia.

OGrady K, Carlin J, Chang A, Torzillo P, Nolan T, Ruben A Bull World Health Organ. 2010; 88(2):139-46.

PMID: 20428371 PMC: 2814482. DOI: 10.2471/BLT.09.068239.


Respiratory infections and lung function in an Australian Aboriginal community.

Musk A, James A, Palmer L, Ryan G, Lake F, Golledge C Respirology. 2008; 13(2):257-62.

PMID: 18339025 PMC: 7192217. DOI: 10.1111/j.1440-1843.2007.01221.x.


Distribution of Streptococcus pneumoniae serotypes responsible for penicillin resistance and the potential role of new conjugate vaccines in New Caledonia.

Michel N, Watson M, Baumann F, Perolat P, Garin B J Clin Microbiol. 2005; 43(12):6060-3.

PMID: 16333099 PMC: 1317162. DOI: 10.1128/JCM.43.12.6060-6063.2005.